Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Last Updated: Tuesday, April 5, 2022
As reported in The New England Journal of Medicine by Aditya Bardia, MD, and colleagues, the phase III ASCENT trial has shown prolonged progression-free and overall survival with the Trop-2–directed antibody-drug conjugate sacituzumab govitecan-hziy vs single-agent chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer without brain metastases (primary trial population).
Advertisement
News & Literature Highlights